# New Phase 2 clinical trials: 7,214 posted since Nov 2024

Updated November 9, 2026.

7,214 clinical studies in phase 2 were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 2,090 have an industry sponsor and 5,959 are recruiting or about to. The newest, NCT07927036, was posted on November 9, 2026: Enhancing the Effect of Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: A... (The Royal's Institute of Mental Health Research).

## The full list

New Phase 2 clinical trials: 7,214 rows for $152.14, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 314 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/phase/phase-2

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 7,214
- Industry sponsored: 2,090
- Recruiting or not yet: 5,959
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 7,214, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07927036 | Enhancing the Effect of Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder: A Double-blind Randomized Controlled... | The Royal's Institute of Mental Health Research | Phase 2 | Not yet recruiting | Posttraumatic Stress Disorder (PTSD) | 126 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927036) |
| November 9, 2026 | NCT07926698 | Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm... | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation, Acute Graft-Versus-Host Disease | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926698) |
| November 9, 2026 | NCT07926477 | Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Colorectal Cancer | 86 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926477) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | Belgium, Finland, Germany, Japan, Mexico, South Korea, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 9, 2026 | NCT07926282 | Adjunctive Melatonin Gel With MINST on GCF Galectin-3 and IL-1 in Stage III-IV Periodontitis | Badr University | Phase 2 | Not yet recruiting | Periodontitis, Periodontitis (Stage 3), Periodontitis Stage IV | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926282) |
| November 9, 2026 | NCT07926217 | High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy | Sung-Han Kim | Phase 2 | Recruiting | Hematologic Malignancy, Influenza | 60 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926217) |
| November 9, 2026 | NCT07925866 | Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immunotherapy | Anhui Provincial Hospital | Phase 2 | Recruiting | Patients With Locally Advanced or Metastatic NSCLC Who Have Failed First-line Immunotherapy | 39 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925866) |
| November 9, 2026 | NCT07925619 | Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers | Pharmosa Biopharm Inc. | Phase 2 | Not yet recruiting | Systemic Sclerosis | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925619) |
| November 9, 2026 | NCT07925554 | Interferon-α Maintenance in Favorable-Risk AML | Peking University People's Hospital | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia) | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925554) |
| November 9, 2026 | NCT07925333 | Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925333) |
| November 9, 2026 | NCT07925268 | Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer | Rahul Aggarwal | Phase 2 | Not yet recruiting | Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925268) |
| November 9, 2026 | NCT07925242 | FAPI PET in Systemic Sclerosis Interstitial Lung Disease | University of California, Los Angeles | Phase 2 | Not yet recruiting | Systemic Sclerosis (SSc), Scleroderma, Interstitial Lung Disease With Systemic Sclerosis | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925242) |
| November 9, 2026 | NCT07924722 | Local Iloprost Therapy to Promote Bone Healing in High Risk Fractures | Charite University, Berlin, Germany | Phase 2 | Not yet recruiting | Nonunion Bone Fracture, Fractures Ununited, Fractures | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924722) |
| November 9, 2026 | NCT07924605 | PSMA PET/MRI for Predicting and Detecting Prostate Cancer | University of Wisconsin, Madison | Phase 2 | Not yet recruiting | Prostate Cancer, High-Risk Localized Prostate Cancer, Locally Advanced Prostate Cancer, Low-Risk Prostate Cancer... | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924605) |
| November 9, 2026 | NCT07924332 | Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction... | Qun Zhao | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 98 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924332) |
| November 9, 2026 | NCT07923877 | Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer | Mayo Clinic | Phase 2 | Not yet recruiting | Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8... | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923877) |
| November 6, 2026 | NCT07923851 | A Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Palmoplantar Pustulosis of Adults | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923851) |
| November 6, 2026 | NCT07923773 | Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) | Novartis Pharmaceuticals | Phase 2 | Not yet recruiting | Moderate to Severe Psoriatic Arthritis | 88 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923773) |
| November 6, 2026 | NCT07923760 | Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use. | University of California, San Diego | Phase 2 | Not yet recruiting | Sleep-disordered Breathing, Chronic Opioid Use | 62 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923760) |
| November 6, 2026 | NCT07923630 | Validation & Intervention Testing for Aging, Longevity and Healthspan | The University of Texas Health Science Center at San Antonio | Phase 2 | Not yet recruiting | Aging, Functional Decline | 1,200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923630) |
| November 6, 2026 | NCT07923617 | Lisdexamfetamine For the Treatment of Conduct Disorder in Children | Orygen | Phase 2 | Not yet recruiting | Conduct Disorder | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923617) |
| November 6, 2026 | NCT07923591 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923591) |
| November 6, 2026 | NCT07923448 | Can TrenibotulinumtoxinE Reverse OnabotulinumtoxinA Effect in Treating Lateral Canthal Lines? | Project Skin MD | Phase 2 | Not yet recruiting | Wrinkles and Rhytides | 4 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923448) |
| November 6, 2026 | NCT07923357 | A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM | 364 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923357) |
| November 6, 2026 | NCT07922928 | Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer | Sun Yat-sen University | Phase 2 | Not yet recruiting | Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922928) |
| November 6, 2026 | NCT07922915 | Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Localized Clear Cell Renal Cell Carcinoma | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922915) |
| November 6, 2026 | NCT07922616 | Intralesional Metformin Versus Triamcinolone for Keloid Treatment | Al-Azhar University | Phase 2 | Completed | Keloids | 30 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922616) |
| November 6, 2026 | NCT07922148 | Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized... | Beckey Trinh | Phase 2 | Not yet recruiting | Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2) | 44 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922148) |
| November 6, 2026 | NCT07921615 | QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Plasmablastic Lymphoma | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921615) |
| November 6, 2026 | NCT07921420 | MF-300 for Treatment of Age-Related Sarcopenia | Epirium Bio Inc. | Phase 2 | Not yet recruiting | Sarcopenia in Elderly | 225 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921420) |
| November 6, 2026 | NCT07921355 | Melatonin in Posterior Mandible Extraction Socket | Cairo University | Phase 2 | Not yet recruiting | Bone Loss | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921355) |
| November 6, 2026 | NCT07921082 | Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II... | Dow University of Health Sciences | Phase 2 | Not yet recruiting | Oral and Maxillofacial Conditions | 20 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921082) |
| November 6, 2026 | NCT07920887 | A Study of Bimagrumab in Participants With HFpEF | Eli Lilly and Company | Phase 2 | Not yet recruiting | Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction, Heart Failure, Preserved... | 540 | Hungary, Italy, Poland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920887) |
| November 6, 2026 | NCT07920835 | A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Phase 2 | Recruiting | Soft Tissue Sarcoma | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920835) |
| November 6, 2026 | NCT07920796 | Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia | Guangdong Second Provincial General Hospital | Phase 2 | Enrolling by invitation | Acute Leukemia, High Risk, Acute Leukemia Refractory, Acute Leukemia, Relapsed | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920796) |
| November 6, 2026 | NCT07920731 | A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer | Fudan University | Phase 2 | Enrolling by invitation | Pancreatic Cancer Metastatic | 45 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920731) |
| November 5, 2026 | NCT07920640 | Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Diabetes Mellitus, Type 2 | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920640) |
| November 5, 2026 | NCT07920393 | Allogeneic Cell Therapy in Refractory T-Cell Lymphoma | University Medical Center Goettingen | Phase 2 | Not yet recruiting | Lymphoma, T Cell, Peripheral | 70 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920393) |
| November 5, 2026 | NCT07920250 | Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal Carcinoma | Affiliated Hospital of Guangdong Medical University | Phase 2 | Completed | Nasopharyngeal Carcinoma (NPC), Radiation-induced Oral Mucositis, Head and Neck Neoplasms | 210 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920250) |
| November 5, 2026 | NCT07920224 | Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | Stomach Neoplasms | 59 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920224) |
| November 5, 2026 | NCT07920185 | A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia in a Randomized, Controlled, Dose-finding Study | Somnum Pharma Inc. | Phase 2 | Not yet recruiting | Chronic Insomnia | 45 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920185) |
| November 5, 2026 | NCT07920159 | Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer | Anhui Provincial Hospital | Phase 2 | Not yet recruiting | High-grade Serous Ovarian Cancer | 76 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920159) |
| November 5, 2026 | NCT07919977 | Romiplostim for Platelet Engraftment After Haploidentical or Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation | Liping Dou | Phase 2 | Recruiting | Hematologic Diseases | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919977) |
| November 5, 2026 | NCT07919821 | Early Feeding TL Trial | University of Florida | Phase 2 | Not yet recruiting | Total Laryngectomy | 120 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919821) |
| November 5, 2026 | NCT07919717 | NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer | 35 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919717) |
| November 5, 2026 | NCT07919691 | Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy | Ruijin Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 44 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919691) |
| November 5, 2026 | NCT07919457 | Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Phase 2 | Recruiting | Chronic Postsurgical Pain, Chronic Post Cancer Surgery Pain, Chronic Post Operative Pain, Radiation Effects... | 40 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919457) |
| November 5, 2026 | NCT07919444 | Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Phase 2 | Recruiting | Cancer Pain, Orofacial Pain, Head and Neck Cancer, Head and Neck (HNSCC) | 40 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919444) |
| November 5, 2026 | NCT07918989 | A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Breast Cancer, Breast Cancer Female | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918989) |
| November 5, 2026 | NCT07918976 | Effects of Inhaled Nitric Oxide on Sublingual Microcirculation in Patients With Right Ventricular Dysfunction After Cardiac Surgery | Southeast University, China | Phase 2 | Completed | Cardiac Surgery Intensive Care Treatment, Pulmonary Hypertension, Right Ventricular (RV) Dysfunction | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918976) |
| November 5, 2026 | NCT07918625 | A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes | BrightGene Bio-Medical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obese Participants Without Diabetes | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918625) |
| November 5, 2026 | NCT07918573 | Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial) | Fondation Raoul Follereau | Phase 2 | Not yet recruiting | Leprosy, Multibacillary | 120 | Benin | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918573) |
| November 5, 2026 | NCT07918274 | Restoring Awareness | Casa Colina Hospital and Centers for Healthcare | Phase 2 | Not yet recruiting | Vegetative State, Minimally Conscious State | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918274) |
| November 5, 2026 | NCT07918079 | Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy | Fudan University | Phase 2 | Not yet recruiting | Breast Cancer | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918079) |
| November 5, 2026 | NCT07917949 | Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 | Recruiting | Soft Tissue Sarcoma | 34 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917949) |
| November 5, 2026 | NCT07917910 | A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB) | Suzhou HepaThera Biotech Co., Ltd. | Phase 2 | Not yet recruiting | Chronic Hepatitis B Virus Infection | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917910) |
| November 5, 2026 | NCT07917832 | Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell Lymphoma | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917832) |
| November 5, 2026 | NCT07917780 | A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With... | German CLL Study Group | Phase 2 | Recruiting | Richter Transformation | 116 | Australia, Austria, Denmark, Germany, Ireland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917780) |
| November 5, 2026 | NCT07917767 | A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of... | Tang-Du Hospital | Phase 2 | Not yet recruiting | NSCLC Stage IIIA/B, NSCLC Stage II | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917767) |
| November 4, 2026 | NCT07917650 | PET/CT-Guided Maintenance Therapy in Previously Untreated MZL | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Active not recruiting | Marginal Zone Lymphoma(MZL) | 45 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917650) |
| November 4, 2026 | NCT07917624 | Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 87 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917624) |
| November 4, 2026 | NCT07917481 | A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular... | MedSIR | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma (HCC) | 44 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917481) |
| November 4, 2026 | NCT07917338 | Oral N-Acetylcysteine on Diabetic Macular Edema | Khadija Ahmed Mhrose Glal | Phase 2 | Recruiting | Diabetic Macular Edema (DME) | 50 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917338) |
| November 4, 2026 | NCT07917104 | Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases... | Fudan University | Phase 2 | Recruiting | Colorectal Cancer Liver Metastases (CRLM), ctDNA | 220 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917104) |
| November 4, 2026 | NCT07917039 | SYH2072 Tablets in Participants With Primary Aldosteronism | InnovStone Therapeutics Limited | Phase 2 | Not yet recruiting | Primary Aldosteronism | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917039) |
| November 4, 2026 | NCT07916740 | Autologous Hair Follicle-Derived Secretome and Platelet-Rich Plasma for Premature Ovarian Insufficiency | Trio Fertility | Phase 2 | Recruiting | Premature Ovarian Insufficiency, POI, Primary Ovarian Insufficiency (Poi), Premature Ovarian Failure (POF) | 15 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916740) |
| November 4, 2026 | NCT07916389 | Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma | St. Jude Children's Research Hospital | Phase 2 | Not yet recruiting | Infant-Type Hemispheric Glioma | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916389) |
| November 4, 2026 | NCT07916324 | Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma | Stanford University | Phase 2 | Not yet recruiting | Scleroderma, Sclerodactyly, Systemic Sclerosis | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916324) |
| November 4, 2026 | NCT07915791 | A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe... | GlaxoSmithKline | Phase 2 | Not yet recruiting | Pulmonary Disease, Chronic Obstructive | 279 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915791) |
| November 4, 2026 | NCT07915687 | Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health | Universiti Teknologi Mara | Phase 2 | Not yet recruiting | Dyslipidemia | 190 | Malaysia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915687) |
| November 4, 2026 | NCT07915258 | Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma of Head and Neck (SCCHN) | 22 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915258) |
| November 4, 2026 | NCT07914855 | Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914855) |
| November 4, 2026 | NCT07914816 | Phase 2 Evaluation of Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) Injection for the Treatment of Infraorbital Hollowing | Lynch Regenerative Medicine | Phase 2 | Not yet recruiting | Infra-orbital Hollows, Skin Quality Improvement | 75 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914816) |
| November 3, 2026 | NCT07914660 | Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a) | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Hyperlipoproteinemia (a) | 192 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914660) |
| November 3, 2026 | NCT07914647 | Remote Ischaemic Conditioning for Fatigue After Stroke 2 (RICFAST 2) | Sheffield Teaching Hospitals NHS Foundation Trust | Phase 2 | Recruiting | Stroke, Fatigue | 60 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914647) |
| November 3, 2026 | NCT07914309 | Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer | Washington University School of Medicine | Phase 2 | Not yet recruiting | Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer | 17 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914309) |
| November 3, 2026 | NCT07914231 | A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis | Coultreon Biopharma | Phase 2 | Not yet recruiting | Plaque Psoriasis | 100 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914231) |
| November 3, 2026 | NCT07914088 | A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis | Arjil Pharmaceuticals LLC | Phase 2 | Recruiting | Dermatitis Atopic | 40 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914088) |
| November 3, 2026 | NCT07914062 | PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates | Antev Ltd. | Phase 2 | Not yet recruiting | Endometriosis Pelvic, Endometriosis Ovaries, Premenopausal, Endometriosis (Diagnosis), Dysmenorrhoea, Dyspareunia... | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914062) |
| November 3, 2026 | NCT07913906 | Alberta Cancer Exercise Dose in Colorectal Cancer | University of Calgary | Phase 2 | Not yet recruiting | Cancer, Colorectal Cancer | 90 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913906) |
| November 3, 2026 | NCT07913763 | Rimonabant for Improving Walking Ability in Patients With Chronic Stroke | Sinfatin S.L | Phase 2 | Not yet recruiting | Chronic Stroke | 80 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913763) |
| November 3, 2026 | NCT07913594 | Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma | Olivia Newton-John Cancer Research Institute | Phase 2 | Not yet recruiting | Peripheral T-Cell Lymphoma Refractory | 25 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913594) |
| November 3, 2026 | NCT07913568 | A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell... | National Cancer Center, Japan | Phase 2 | Not yet recruiting | Ovarian Clear Cell Carcinoma | 32 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913568) |
| November 3, 2026 | NCT07913542 | N-Acetylcysteine for Bipolar and Alcohol Use Disorders | Medical University of South Carolina | Phase 2 | Not yet recruiting | Bipolar Disorder, Alcohol Use Disorder | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913542) |
| November 3, 2026 | NCT07913165 | A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma... | Tao Zhang | Phase 2 | Not yet recruiting | Gastric Cancer (GC) | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913165) |
| November 3, 2026 | NCT07913074 | A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With... | Tavo Biotherapeutics | Phase 2 | Recruiting | Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT) | 96 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913074) |
| November 3, 2026 | NCT07912996 | Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes | Gilead Sciences | Phase 2 | Not yet recruiting | HSV-2 Infection | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912996) |
| November 3, 2026 | NCT07912957 | Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ | Fudan University | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | 62 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912957) |
| November 3, 2026 | NCT07912606 | D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 32 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912606) |
| November 3, 2026 | NCT07911995 | A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants... | Grünenthal GmbH | Phase 2 | Not yet recruiting | Duchenne Muscular Dystrophy (DMD) | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911995) |
| November 3, 2026 | NCT07911891 | Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer | Li Zhihui | Phase 2 | Completed | Thyroid Cancer, Hand-foot Syndrome | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911891) |
| November 3, 2026 | NCT07911735 | A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patients | InnovStone Therapeutics Limited | Phase 2 | Not yet recruiting | Uncontrolled Hypertension, Resistant Hypertension | 264 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911735) |
| November 3, 2026 | NCT07911683 | Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma | BeOne Medicines | Phase 2 | Not yet recruiting | Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911683) |
| November 2, 2026 | NCT07911449 | Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases | Cho Ray Hospital | Phase 2 | Recruiting | Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Activating Mutation | 41 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911449) |
| November 2, 2026 | NCT07911280 | A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy | Samsung Medical Center | Phase 2 | Recruiting | Gastric Cancer | 20 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911280) |
| November 2, 2026 | NCT07911124 | Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease | University of Arkansas | Phase 2 | Not yet recruiting | Chronic Kidney Disease (CKD) | 230 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911124) |
| November 2, 2026 | NCT07910630 | A Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular Traction | Jiangsu Jingze Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Vitreomacular Traction (VMT) | 48 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910630) |
| November 2, 2026 | NCT07910435 | Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial | University of Washington | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 27 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910435) |
| November 2, 2026 | NCT07909889 | Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer | Aarhus University Hospital | Phase 2 | Not yet recruiting | Breast Cancer (Early Breast Cancer), Obesity | 32 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909889) |
| November 2, 2026 | NCT07909863 | Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909863) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Fudan University | 164 | November 6, 2026 |
| Sun Yat-sen University | 156 | November 6, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 116 | November 2, 2026 |
| M.D. Anderson Cancer Center | 73 | November 5, 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | 66 | November 6, 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 66 | November 4, 2026 |
| The First Affiliated Hospital with Nanjing Medical University | 66 | November 3, 2026 |
| Ruijin Hospital | 60 | November 5, 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 57 | November 9, 2026 |
| Memorial Sloan Kettering Cancer Center | 51 | November 5, 2026 |
| Peking Union Medical College Hospital | 41 | October 16, 2026 |
| Novartis Pharmaceuticals | 38 | November 6, 2026 |
| Eli Lilly and Company | 38 | November 6, 2026 |
| Washington University School of Medicine | 38 | November 3, 2026 |
| Shanghai Zhongshan Hospital | 37 | November 5, 2026 |
| Merck Sharp & Dohme LLC | 37 | October 26, 2026 |
| Mayo Clinic | 36 | November 9, 2026 |
| National Cancer Institute (NCI) | 35 | November 4, 2026 |
| West China Hospital | 35 | October 29, 2026 |
| AstraZeneca | 35 | August 19, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 275 | November 5, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 245 | November 5, 2026 |
| [Colorectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/colorectal-neoplasms) | 151 | November 9, 2026 |
| [Obesity](https://specstream.ai/data/clinical-trials/condition/obesity) | 141 | November 2, 2026 |
| [Carcinoma, Hepatocellular](https://specstream.ai/data/clinical-trials/condition/carcinoma-hepatocellular) | 124 | November 5, 2026 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 120 | November 9, 2026 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 111 | November 3, 2026 |
| [Recurrence](https://specstream.ai/data/clinical-trials/condition/recurrence) | 109 | November 6, 2026 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 104 | October 22, 2026 |
| [Squamous Cell Carcinoma of Head and Neck](https://specstream.ai/data/clinical-trials/condition/squamous-cell-carcinoma-of-head-and-neck) | 103 | November 9, 2026 |
| [Leukemia, Myeloid, Acute](https://specstream.ai/data/clinical-trials/condition/leukemia-myeloid-acute) | 96 | November 9, 2026 |
| [Overweight](https://specstream.ai/data/clinical-trials/condition/overweight) | 92 | November 5, 2026 |
| [Stomach Neoplasms](https://specstream.ai/data/clinical-trials/condition/stomach-neoplasms) | 89 | November 5, 2026 |
| [Triple Negative Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/triple-negative-breast-neoplasms) | 87 | November 3, 2026 |
| [Neoplasm Metastasis](https://specstream.ai/data/clinical-trials/condition/neoplasm-metastasis) | 75 | October 29, 2026 |
| [Pancreatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/pancreatic-neoplasms) | 72 | October 26, 2026 |
| [Rectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/rectal-neoplasms) | 72 | October 22, 2026 |
| [Diabetes Mellitus, Type 2](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-2) | 71 | November 6, 2026 |
| [Multiple Myeloma](https://specstream.ai/data/clinical-trials/condition/multiple-myeloma) | 67 | October 29, 2026 |
| [Head and Neck Neoplasms](https://specstream.ai/data/clinical-trials/condition/head-and-neck-neoplasms) | 66 | November 5, 2026 |
| [Lymphoma, Large B-Cell, Diffuse](https://specstream.ai/data/clinical-trials/condition/lymphoma-large-b-cell-diffuse) | 65 | November 4, 2026 |
| [Uterine Cervical Neoplasms](https://specstream.ai/data/clinical-trials/condition/uterine-cervical-neoplasms) | 64 | August 18, 2026 |
| [Carcinoma, Renal Cell](https://specstream.ai/data/clinical-trials/condition/carcinoma-renal-cell) | 61 | November 9, 2026 |
| [Small Cell Lung Carcinoma](https://specstream.ai/data/clinical-trials/condition/small-cell-lung-carcinoma) | 61 | November 2, 2026 |
| [Alzheimer Disease](https://specstream.ai/data/clinical-trials/condition/alzheimer-disease) | 61 | October 29, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 2,502 | November 9, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 2,201 | November 9, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 356 | November 9, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 350 | October 20, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 334 | November 9, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 264 | November 6, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 254 | November 3, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 252 | November 9, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 247 | November 5, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 210 | November 6, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 202 | November 9, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 187 | November 9, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 143 | November 6, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 134 | November 3, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 125 | October 29, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 123 | October 6, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 106 | October 22, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 102 | November 9, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 84 | September 29, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 76 | November 5, 2026 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 75 | November 6, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 71 | October 26, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 63 | November 6, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 61 | September 24, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 61 | September 9, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).